We believe in true innovation.

LigaSure™ technology has been used in more than 25 million procedures worldwide.1

The LigaSure™ Maryland jaw thoracic device (LF1930T) is the first and only minimally invasive LigaSure™ device on the market specifically indicated for sealing pulmonary veins and arteries/vessels up to, and including, 7 mm.2

The LigaSure™ Maryland Jaw Thoracic Device

REASONS TO ENERGISE YOUR PROCEDURES

7 Reasons Why you want to bring the Right Energy to your thoracic cases with the Ligasure™ Maryland jaw thoracic device (LF1930T):

1. Reliable hemostasis  For 7 mm pulmonary vasculature, the device also seals and transects adhesions2–8.

2. Better visualization The curved jaw allows for better access, visualization and easy skeletonization of vessels9,10.

3. Access 30 cm shaft designed specifically for access to the thoracic cavity4–8.

4. Effective blunt dissection For dissecting around the recurrent nerve and lymph nodes without causing damage9,11.

5. Cooler jaws Cooler jaw temperature and faster cool down times compared to Harmonic HD1000i™*9,12,§.

6. Multifunctionality The device has the benefits of being a Maryland dissector9,11, one – step sealer13, atraumatic grasper9,11, cold scissors9,13 and it may reduce instrument exchanges9,10 and procedure time9,14.

7. Coated jaws Proprietary nano‑coating on the jaws to reduce sticking9,15,Φ, eschar buildup15,16 and cleanings9,17,Ω.

Harvey Cushing – Neurosugeron and William Bovie – BioPhisical Engineer collaborate in the development of modern dyatermy unit.

Expanding product development, the first portable, solid‑state electrosurgical generator, the SSE1, is introduced into the marketplace.

This technology uses transistors and solid‑state circuitry, replacing the old Bovie™* vacuum tubes and spark gaps.

The first REM™ system is launched, which ensures pad contact by monitoring a patient’s impedance levels. This system automatically deactivates the generator if a change in patient/pad impedance levels occurs, reducing the potential for pad site burns.

Instant Response™ technology is introduced to the operating room in the Force FX™ electrosurgical generator. This smart generator technology uses computer‑controlled output for automatic response to changes in tissue density across all tissue types.

Continuing Valleylab’s history of firsts, the ForceTriad™ energy platform is released, featuring TissueFect™ sensing technology – a control system designed to precisely manage energy delivery, creating a range of options for desired tissue effect. The energy platform combines monopolar, bipolar and LigaSure™ tissue fusion all in one unit.

Continuing to meet surgeon needs, the LigaSure Advance™ instrument combines tissue fusion, Valleylab™ mode tissue dissection energy and sterile‑field power control in one multifunctional instrument for laparoscopic procedures. LigaSure™ Blunt Tip LF1537

LigaSure™ Blunt Tip LF1637

LigaSure Impact™ (Gen2) LF4318

Valleylab™ LS10

LigaSure™ Blunt Tip (Gen2) 23/44cm

LigaSure™ Curved Jaw

LigaSure Blunt Tip (Gen3) with Nano‑Coating Technology LF18XX

LigaSure™ Impact (Gen3) with Nano‑Coating Technology LF4418

LigaSure™ Maryland (Gen3) with Nano‑Coating Technology LF19XX

LigaSure™ Maryland Thoracic LF1930T

1926 1967 1968 1970 1981 1983 1995 1999 2006 2007 2008 2009 2010 2011 2013 2014 2015 2016 2017 2018 2020

The company is founded as a medical products distributor, but soon begins developing “firsts” in electrosurgical products.

In response to surgeon needs, the first reusable hand‑switching pencil is developed, which allows the surgeon to activate the electrosurgical generator by hand. This reduces the fatigue associated with foot‑switching devices.

The same year, the first isolated generator is introduced to the market. By removing the ground as a reference for the circuit and isolating the circuit within the generator, current division and alternate site burns are reduced.

The first microprocessor‑based electrosurgical generator, the SSE4, is introduced to the market. The new unit provides a more intelligent user‑interface.

The first power‑control pencil is introduced, allowing the surgeon to control the generator power from the sterile field.

The next‑generation “adaptive” REM™ system, exclusive to Valleylab, adapts to individual patients and improves the sensitivity to changes in contact impedance levels, increasing the potential for patient safety. The development of PolyHesive™ gel, the first water‑based hydrogel, enhances skin conductivity and minimizes heat buildup in Valleylab patient return electrodes.

The LigaSure™ vessel sealing system, the first energy‑based ligation system, revolutionizes electrosurgery. The system seals vessels and tissue bundles without sutures or clips.

The Force TriVerse™ electrosurgical device is the first monopolar instrument to provide both sterile‑field power control and access to the Valleylab™ mode energy modality. Using preset power bars on the ForceTriad™ energy platform, surgeons are able to make precise power adjustments from the sterile field. In addition, the Valleylab™ mode button provides an additional option – hemostasis with controlled dissection – as well as Cut and Coag.

The LigaSure Impact™ instrument is the first tissue fusion instrument developed to incoporate the TissueFect™ sensing technology provided by the ForceTriad™ energy platform.

LigaSure Advance™ LigaSure™ Small Jaw LigaSure™ Maryland (23/44 cm launched in 2015)

Valleylab™ FT10 LigaSure™ Hook 37/44cm LF56XX

LigaSure™ Exact Dissector

VALLEYLAB™ 50 YEARS OF CONFIDENCE

Harvey Cushing – Neurosugeron and William Bovie – BioPhisical Engineer collaborate in the development of modern dyatermy unit.

Expanding product development, the first portable, solid‑state electrosurgical generator, the SSE1, is introduced into the marketplace.

This technology uses transistors and solid‑state circuitry, replacing the old Bovie™* vacuum tubes and spark gaps.

The first REM™ system is launched, which ensures pad contact by monitoring a patient’s impedance levels. This system automatically deactivates the generator if a change in patient/pad impedance levels occurs, reducing the potential for pad site burns.

Instant Response™ technology is introduced to the operating room in the Force FX™ electrosurgical generator. This smart generator technology uses computer‑controlled output for automatic response to changes in tissue density across all tissue types.

Continuing Valleylab’s history of firsts, the ForceTriad™ energy platform is released, featuring TissueFect™ sensing technology – a control system designed to precisely manage energy delivery, creating a range of options for desired tissue effect. The energy platform combines monopolar, bipolar and LigaSure™ tissue fusion all in one unit.

Continuing to meet surgeon needs, the LigaSure Advance™ instrument combines tissue fusion, Valleylab™ mode tissue dissection energy and sterile‑field power control in one multifunctional instrument for laparoscopic procedures. LigaSure™ Blunt Tip LF1537

LigaSure™ Blunt Tip LF1637

LigaSure Impact™ (Gen2) LF4318

Valleylab™ LS10

LigaSure™ Blunt Tip (Gen2) 23/44cm

LigaSure™ Curved Jaw

LigaSure Blunt Tip (Gen3) with Nano‑Coating Technology LF18XX

LigaSure™ Impact (Gen3) with Nano‑Coating Technology LF4418

LigaSure™ Maryland (Gen3) with Nano‑Coating Technology LF19XX

LigaSure™ Maryland Thoracic LF1930T

1926 1967 1968 1970 1981 1983 1995 1999 2006 2007 2008 2009 2010 2011 2013 2014 2015 2016 2017 2018 2020

The company is founded as a medical products distributor, but soon begins developing “firsts” in electrosurgical products.

In response to surgeon needs, the first reusable hand‑switching pencil is developed, which allows the surgeon to activate the electrosurgical generator by hand. This reduces the fatigue associated with foot‑switching devices.

The same year, the first isolated generator is introduced to the market. By removing the ground as a reference for the circuit and isolating the circuit within the generator, current division and alternate site burns are reduced.

The first microprocessor‑based electrosurgical generator, the SSE4, is introduced to the market. The new unit provides a more intelligent user‑interface.

The first power‑control pencil is introduced, allowing the surgeon to control the generator power from the sterile field.

The next‑generation “adaptive” REM™ system, exclusive to Valleylab, adapts to individual patients and improves the sensitivity to changes in contact impedance levels, increasing the potential for patient safety. The development of PolyHesive™ gel, the first water‑based hydrogel, enhances skin conductivity and minimizes heat buildup in Valleylab patient return electrodes.

The LigaSure™ vessel sealing system, the first energy‑based ligation system, revolutionizes electrosurgery. The system seals vessels and tissue bundles without sutures or clips.

The Force TriVerse™ electrosurgical device is the first monopolar instrument to provide both sterile‑field power control and access to the Valleylab™ mode energy modality. Using preset power bars on the ForceTriad™ energy platform, surgeons are able to make precise power adjustments from the sterile field. In addition, the Valleylab™ mode button provides an additional option – hemostasis with controlled dissection – as well as Cut and Coag.

The LigaSure Impact™ instrument is the first tissue fusion instrument developed to incoporate the TissueFect™ sensing technology provided by the ForceTriad™ energy platform.

LigaSure Advance™ LigaSure™ Small Jaw LigaSure™ Maryland (23/44 cm launched in 2015)

Valleylab™ FT10 LigaSure™ Hook 37/44cm LF56XX

LigaSure™ Exact Dissector

VALLEYLAB™

50 YEARS OF INNOVATION

IMPORTANT: Please refer to the package insert for complete instructions, contraindications, warnings and precautions.

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. 20‑emea‑ls‑maryland‑thoracic‑7‑reasons‑why‑booklet‑3953333

medtronic.com/covidien/uk/vessel-sealing

Photo credit: Getty Images

A COMPLETEVATS LOBECTOMYSOLUTION

We offer comprehensive lung care solutions. Here is an example of how our technologies can make an impact on VATS lobectomies.

REFERENCES† Based on a US database search of Ethicon Enseal, Harmonic, Olympus Thunderbeat, Medtronic, Applied Medical,

Aesculap devices (March 10, 2019).

§ Based on systemic vasculature.

Φ Tissue sticking to device jaws instances measured over 110 seals per device (ForceTriad™ energy platform). F1930T is only compatible with the Valleylab™ FT10 energy platform.

Ω Cleaning effectiveness assessed after each of two cleaning cycles.

1. Based on internal sales data from FY01‑FY20. October 2019.

2. Based on internal report #RE00147462, Pulmonary sealing claims for the LigaSure™ LF1930T device (memo). March 29, 2018.

3. LigaSure™ Maryland Jaw Thoracic Sealer/Divider, Nano‑Coated [instructions for use]. Boulder, CO: Medtronic; 2017. ±As of Nov. 19, 2018, based on indications for use for laparoscopic LigaSure™ devices.

4. Based on internal report #RE00138840, LIG‑45 memo, device length recommendation, thoracic (LF1930T). Feb. 6, 2018.

5. Based on internal test report #RE00125866, Jaw force and gap range burst pressure evaluation of EB4 thoracic Maryland device (LF1930T); conducted on bovine tissue. Nov. 20 –21, 2017 and Nov. 27–30, 2017.

6. Based on internal test report #RE00134865, Burst pressure verification of pulmonary bovine veins using the LigaSure™ LF1930T device. Jan. 17–18, 2018.

7. Based on internal test report #RE00122515, Verification of the LigaSure™ LF1930T device in a GLP chronic hemostasis canine study on pulmonary vasculature. Jan. 8–10, 2018.

8. Based on internal test report #RE00128442, GLP acute pulmonary vasculature hemostasis verification study of the LigaSure™ LF1930T device in hounds. Dec. 8, 2017

9. Based on internal test report #RE00140529 rev A, LigaSure™ Maryland device, nano‑coated (LF19X X) tissue testing (memo). March 5, 2018

10. Based on internal test report #RE00071598, Maryland validation labs, Houston and Los Angeles: independent surgeon feedback collected during porcine labs. April 16–18 and April 30 –May 3, 2013. ≠ 30 of 33 surgeons surveyed after use.

11. Based on internal test report #R0035742, Maryland validation, Houston and Los Angeles: independent surgeon feedback collected during porcine labs. April 16–18 and April 30–May 3, 2013.

12. Based on internal test report #R0032385 rev A, Thermal profile comparison of Ethicon Harmonic™* HD1000i shears versus nano‑coated LigaSure™ Maryland jaw device on the Valleylab™ FT10 energy platform. May 17–18, 2017 and June 14, 2017.

13. LigaSure™ Maryland Jaw Sealer/Divider, Nano‑Coated [instructions for use]. Boulder, CO: Medtronic; 2016.

14. Okada M, Miyata Y, Takamochi K, Tsutani Y, Oh S, Suzuki K. Prospective feasibility study of sealing pulmonary vessels with energy in lung surgery. J Thorac Cardiovasc Sur. 2018.

15. Based on internal test report #RE00073194, Tissue sticking comparison of the Ethicon G2™*, Voyant™* 5 mm Fusion, LigaSure™ LF1737, and LigaSure™ LF1937 devices conducted on porcine tissue using the ForceTriad™ energy platform. Jan. 18, 2017.

16. Based on internal report #RE00147462, Pulmonary sealing claims for the LigaSure™LF1930T device (memo). March 29, 2018.

17. Based on internal test report #RE00071599, LF19XX MJC marketing claims testing conducted on porcine tissue, Feb. 7–22, 2017.

THROUGHOUT THE PROCEDURE

LUNG MOBILIZATION

DIVISION OF CRITICAL STRUCTURES

Mediastinal lymph node dissection

Step 1:Lysis of adhesions

Step 2:Dissect hilum

Step 3:Ligate and divide pulmonary vessels

Step 4:Divide bronchus

Step 5:Complete the fissure

Tri‑Staple™

2.0 Specialty Reloads

LigaSure™ Maryland Jaw Thoracic Device